Even if GLI inhibitors have shown promising results in preclinical studies, few of them have entered in clinical studies, and only the Arsenic Trioxide (ATO) has been approved by FDA for the treatment of AML [33,34,51,200]. Here, GLI1 is linked to acute myeloid leukemia.